Glympse Bio, a Cambridge, Mass.-based company advancing in vivo sensing technology dedicated to transforming disease monitoring, raised $22m in Series A funding.
The round was co-led by LS Polaris Innovation Fund and ARCH Ventures, with participation from new investors Charles River Ventures, Gilead Sciences, Yonghua Capital, and Inevitable Ventures and existing investors GreatPoint Ventures, Heritage Provider Network and Rivas Capital. Polaris’ Amy Schulman, diagnostics industry veteran Stan Lapidus, and seven-time Forbes’ Midas List recipient Theresia Gouw will join Glympse’s Board of Directors, the company added.
The company intends to use the proceeds to conduct clinical trials for its novel platform
A spin-out from the laboratory of Sangeeta Bhatia, M.D., Ph.D. at the Massachusetts Institute of Technology, Glympse Bio is advancing a novel platform which uses bioengineered activity sensors to noninvasively detect human diseases and to monitor drug response.
This financing follows an initial $6.6 million seed round in 2015 led by Kiran Mazumdar-Shaw at Biocon India Ltd and Theresia Gouw at Aspect Ventures.
Glympse’s activity sensors are bioengineered to be transported to the site of disease in patients, directly interrogate the biological activity of the diseased tissue, and emit a signal which can be detected noninvasively from the recipient’s urine. The sensors can be administered in a minimally invasive manner, and the analytical read-out can be selected based on the disease characteristics or market needs for the test.
The company’s lead indication targets non-alcoholic steatohepatitis (NASH).
Glympse has signed multiple collaborations in NASH with pharmaceutical companies.
The co-founders of the company are:
– Sangeeta Bhatia, M.D. Ph.D., the John J. and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science at the Massachusetts Institute of Technology (MIT);
– Gabriel Kwong, Ph.D., an Assistant Professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech School of Engineering and Emory School of Medicine.